Novartis: Diabetes Mellitus, Type 2 trials
The registry lists 122 Diabetes Mellitus, Type 2 studies with Novartis as lead sponsor. 0 are open to participants now and 27 have results posted.
Phase 1 13Phase 2 23Phase 3 66Phase 4 30(a study in two phases counts in both)
Studies
Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DMTerminatedNCT05199090Phase 2Results posted
- Effect of LIK066 on Reduction of Fatty Content in Livers of Obese PatientsCompletedNCT03205150Phase 2Results posted
- A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart FailureTerminatedNCT03152552Phase 2Results posted
- Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 DiabetesCompletedNCT03005288Phase 2Results posted
- Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months.CompletedNCT02670928Phase 4Results posted
- Effect of LIK066 on Body Weight in Patients With Elevated Body Mass IndexCompletedNCT02470403Phase 2Results posted
- Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and GlimepirideCompletedNCT02007278Phase 4Results posted
- Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM PatientsCompletedNCT02002221Phase 4Results posted
- Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes MellitusCompletedNCT01915849Phase 1/2Results posted
- Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic PatientsTerminatedNCT01910441Phase 4Results posted
- Vildagliptin/Metformin in T2DM Patients Starting Basal InsulinCompletedNCT01871558Phase 3Results posted
- Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin MonotherapyCompletedNCT01811485Phase 3Results posted
- Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by MetforminCompletedNCT01766778Phase 4Results posted
- Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart FunctionCompletedNCT01686932Phase 4Results posted
- Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus PatientsCompletedNCT01582243Phase 4Results posted
- VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes MellitusCompletedNCT01528254Phase 4Results posted
- To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes TherapiesCompletedNCT01068860Phase 2Results posted
- Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin SecretionCompletedNCT01030952Phase 4Results posted
- Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT PatientsCompletedNCT00995930Phase 2Results posted
- Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory FactorsCompletedNCT00928889Phase 4Results posted
- Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes MellitusCompletedNCT00927394Phase 4Results posted
- Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic PatientsTerminatedNCT00900146Phase 2/3Results posted
- Efficacy of Aliskiren in the Treatment of Diabetic Macular EdemaTerminatedNCT00768040Phase 2Results posted
- A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes MellitusCompletedNCT00660309Phase 4Results posted
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 DiabetesCompletedNCT00605475Phase 2Results posted
- Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)TerminatedNCT00549757Phase 3Results posted
- Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular ComplicationsCompletedNCT00097786Phase 3Results posted
- Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II DiabetesTerminatedNCT01862263Phase 4
- Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With DiabetesWithdrawnNCT01824264Phase 2
- Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During RamadanCompletedNCT01758380Phase 4
- Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients.CompletedNCT01649466Phase 4
- Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763CompletedNCT01619332Phase 1/2
- Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes MellitusCompletedNCT01582230Phase 3
- Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)CompletedNCT01541956Phase 4
- Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both MedicationsCompletedNCT01518101Phase 4
- Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 DiabetesCompletedNCT01497522Phase 3
- Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With MetforminCompletedNCT01426802Phase 4
- Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)CompletedNCT01407003Phase 1/2
- Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering EfficacyCompletedNCT01398592Phase 4
- Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 DiabetesCompletedNCT01357252Phase 3
- Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin in Patients With Type 2 DiabetesCompletedNCT01356381Phase 4
- Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 DiabetesCompletedNCT01309698Phase 4
- Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.CompletedNCT01262586Phase 3
- Safety and Efficacy of Galvus in Elderly Type 2 Diabetes PatientsCompletedNCT01257451Phase 3
- Phase 4 Study in the Elderly Patients With T2DMCompletedNCT01238978Phase 4
- Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus GlimepirideCompletedNCT01233622Phase 3
- Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes MellitusCompletedNCT01224366Phase 3
- Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)CompletedNCT01196546Phase 4
- Glycemic Holter Study (Continuous Glucose Monitoring) -CompletedNCT01193296Phase 4
- Long-term Safety Study of Vildagliptin in Patients With Type 2 DiabetesCompletedNCT01159249Phase 3
- To Demonstrate the Effect of Food on the Bioavailability of GlipizideCompletedNCT00947024Phase 1
- To Demonstrate the Relative Bioequivalency Comparing Geneva's 10 mg Glipizide Tablets To Roerig's 10 mg Glucotrol TabletsCompletedNCT00946504Phase 1
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)CompletedNCT00901979Phase 2
- Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart FailureCompletedNCT00894868Phase 4
- To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting ConditionsCompletedNCT00882882Phase 1
- A Relative Bioavailability Study of Metformin HCL Tablets, 1000 mg Under Fasting ConditionsCompletedNCT00865033Phase 1
- Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 DiabetesCompletedNCT00860288Phase 2/3
- Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin MonotherapyCompletedNCT00822211Phase 3
- Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 DiabetesCompletedNCT00821977Phase 2/3
- Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)CompletedNCT00770081Phase 3
- Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)CompletedNCT00765830Phase 3
- Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)CompletedNCT00728351Phase 3
- Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal InsufficiencyCompletedNCT00646542Phase 3
- Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 DiabetesTerminatedNCT00633997Phase 1/2
- Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal InsufficiencyCompletedNCT00616811Phase 3
- Pharmacokinetic Study of LAF237 and Its Metabolites in Mild Renal Impaired PatientsCompletedNCT00572650Phase 1
- Pharmacokinetic Study of Vildagliptin in Patients With Renal ImpairmentCompletedNCT00567047Phase 1
- Vildagliptin 100 mg Once Daily vs. Placebo as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With MetforminCompletedNCT00494884Phase 3
- A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus MetforminCompletedNCT00468039Phase 3
- Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic NephropathyCompletedNCT00464880Phase 1/2
- Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt NephropathyCompletedNCT00464776Phase 1/2
- Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 DiabetesCompletedNCT00461136Phase 1/2
- Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or RosiglitazoneCompletedNCT00402909Phase 4
- Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin AloneCompletedNCT00396357Phase 3
- Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin AloneCompletedNCT00396227Phase 3
- Efficacy and Safety of Vildagliptin Compared to Placebo on the Incretin Effect in Patients With Type 2 Diabetes Treated With MetforminCompletedNCT00396071Phase 3
- Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 DiabetesCompletedNCT00390520Phase 3
- Long Term Safety of Vildagliptin (100mg qd) In Patients With Type 2 DiabetesCompletedNCT00389415Phase 3
- Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 DiabetesCompletedNCT00383578Phase 3
- Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 DiabetesCompletedNCT00382096Phase 3
- Effect of Vildagliptin on Fat and Muscle Metabolism in Patients With Type 2 DiabetesCompletedNCT00380445Phase 3
- A Study to Assess the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes.CompletedNCT00380380Phase 3
- To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 DiabetesCompletedNCT00368134Phase 3
- Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in Patients With Type 2 DiabetesCompletedNCT00351884Phase 3
- A Study To Compare the Effect of Vildagliptin Compared to Placebo in Patients With Type 2 DiabetesCompletedNCT00351832Phase 3
- A Study to Evaluate the Effect of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 DiabetesCompletedNCT00351585Phase 3
- A Study to Assess the Effects of DPP-4 Inhibition on Insulin Sensitivity in Type 2 DiabetesCompletedNCT00351546Phase 3
- A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 DiabetesCompletedNCT00351507Phase 3
- Long-Term Safety Study of Vildagliptin in Patients With Type 2 DiabetesCompletedNCT00325429Phase 3
- To Assess the Efficacy and Safety of Vildagliptin as Add-on Therapy to Sulfonylurea in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea MonotherapyCompletedNCT00325117Phase 3
- A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild HyperglycemiaCompletedNCT00300287Phase 3
- A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 DiabetesCompletedNCT00260156Phase 3
- Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes MellitusCompletedNCT00241085Phase 4
- A Clinical Study to Assess the Efficacy and Safety of Vildagliptin in Patients With Type 2 DiabetesCompletedNCT00238498Phase 2
- A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin ExcretionCompletedNCT00238472Phase 4
- Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 DiabetesCompletedNCT00237237Phase 3
- A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+BenazeprilTerminatedNCT00171119Phase 4
- Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 DiabetesCompletedNCT00138619Phase 3
- Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 DiabetesCompletedNCT00138606Phase 3
- Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With Hemoglobin A1c (HbA1c) 9-11%CompletedNCT00138593Phase 3